INMB
INMB
NASDAQ · Biotechnology

Inmune Bio Inc

$1.12
-0.08 (-6.67%)
As of Mar 29, 10:51 PM ET ·
Financial Highlights (FY 2026)
Revenue
18.3K
Net Income
-55,175,308
Gross Margin
Profit Margin
-300,585.7%
Rev Growth
-57.3%
D/E Ratio
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 61.9% 61.9%
Operating Margin -304,535.7% -274,085.7% 16.6% 15.4%
Profit Margin -300,585.7% -285,556.4% 15.9% 12.3%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 18.3K 42.9K 11.20M 11.67M
Gross Profit 6.93M 7.23M
Operating Income -55,742,216 -117,516,969 1.85M 1.79M
Net Income -55,175,308 -116,321,801 1.78M 1.44M
Gross Margin 61.9% 61.9%
Operating Margin -304,535.7% -274,085.7% 16.6% 15.4%
Profit Margin -300,585.7% -285,556.4% 15.9% 12.3%
Rev Growth -57.3% -57.3% +3.1% +2.1%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 0 0 11.90M 13.58M
Total Equity 32.54M 29.49M
D/E Ratio 0.37 0.46
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -54,139,790 -120,479,738 2.32M 2.58M
Free Cash Flow 977.1K 708.5K